# Cell manufacturing for cell-based tissue engineering: a focus on vascularized, skeletal muscle regeneration

**Authors:** Bruno de Medeiros Cartaxo Esmeraldo, Keely A. Laurence, Brian J. Kwee

PMC · DOI: 10.3389/fceng.2025.1637075 · Frontiers in chemical engineering · 2026-03-24

## TL;DR

This review explores cell manufacturing techniques for creating vascularized skeletal muscle tissue, emphasizing methods to maintain cell potency and address cellular heterogeneity.

## Contribution

The paper introduces emerging tools and methods for managing cellular heterogeneity in biomanufacturing for tissue engineering.

## Key findings

- Current cell manufacturing methods include bioreactors and chemical cues for tissue engineering.
- Maintaining cellular identity and potency during expansion is critical for functional tissue formation.
- Regulatory frameworks and new tools are essential for producing heterogeneous, native-like tissues.

## Abstract

Cell manufacturing processes play a crucial role in cell-based tissue engineering by isolating, purifying, culturing, expanding, modifying, cryopreserving, and formulating patient-derived cells in vitro before utilizing them for tissue regeneration. Currently, researchers apply various methods for cell manufacturing, including bioreactors, defined chemical cues, and substrate modifications. However, factors such as loss of cell potency and heterogeneity are critical challenges when engineering tissues for regenerative medicine. In particular, neglecting cellular heterogeneity during cell expansion prevents the formation of tissues that recapitulate the structural and cellular heterogeneity of our native tissues. This review discusses current and emerging approaches for cell manufacturing, with a focus on biomanufacturing for vascularized, skeletal muscle tissue engineering. Specifically, this review highlights 1) the U.S. Food and Drug Administration’s regulation of manufacturing for cell therapies, 2) state-of-the-art approaches for manufacturing endothelial cells and muscle stem cells that maintain cellular identity and potency, and 3) emerging tools and methods for measuring and manipulating cellular heterogeneities. Ultimately, these approaches can be leveraged to manufacture and formulate tissue-engineered products that mimic the heterogeneous form and function of our native tissues.

## Full-text entities

- **Genes:** IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, ALCAM (activated leukocyte cell adhesion molecule) [NCBI Gene 214] {aka CD166, MEMD}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, DMD (dystrophin) [NCBI Gene 1756] {aka BMD, CMD3B, DXS142, DXS164, DXS206, DXS230}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, LOC536229 (paired box protein Pax-7) [NCBI Gene 536229] {aka PAX7}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, NLRX1 (NLR family member X1) [NCBI Gene 79671] {aka CLR11.3, DLNB26, NOD26, NOD5, NOD9}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, EFNB2 (ephrin B2) [NCBI Gene 1948] {aka EPLG5, HTKL, Htk-L, LERK5, ephrin-B2}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CD34 (CD34 molecule) [NCBI Gene 947], ATXN1 (ataxin 1) [NCBI Gene 6310] {aka ATX1, D6S504E, SCA1}, Mapk11 (mitogen-activated protein kinase 11) [NCBI Gene 19094] {aka P38b, Prkm11, Sapk2, Sapk2b, p38-2, p38beta}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, ANGPT2 (angiopoietin 2) [NCBI Gene 285] {aka AGPT2, ANG2, LMPHM10}, CAV1 (caveolin 1) [NCBI Gene 857] {aka BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, FLRT2 (fibronectin leucine rich transmembrane protein 2) [NCBI Gene 23768]
- **Diseases:** Duchenne Muscular Dystrophy (MESH:D020388), muscle injury (MESH:D009135), pancreatic ductal adenocarcinoma (MESH:D021441), ischemic (MESH:D002545), cancer (MESH:D009369), fibrosis (MESH:D005355), atrophy (MESH:D001284), Cytotoxicity (MESH:D064420), chronic inflammation (MESH:D007249), Muscular Sarcoidosis (MESH:D012507), ischemia (MESH:D007511), diabetic (MESH:D003920)
- **Chemicals:** PKH26 (MESH:C070080), BioRender (-), TCPS (MESH:C049563), heavy metal (MESH:D019216), polyethylene glycol (MESH:D011092), beta-glycerophosphate (MESH:C031463), DMSO (MESH:D004121), polystyrene (MESH:D011137), L-Ascorbic acid (MESH:D001205), alginate (MESH:D000464), chitosan (MESH:D048271), CytoDEX (MESH:C052839)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bos taurus (bovine, species) [taxon 9913], Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** SKGM-2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13008308/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13008308/full.md

## References

106 references — full list in the complete paper: https://tomesphere.com/paper/PMC13008308/full.md

---
Source: https://tomesphere.com/paper/PMC13008308